Brainsway Gets FDA Approval for Multi-Center Bipolar Trial

Brainsway Ltd. (BRIN) said it received approval from the U.S. Food and Drug Administration to begin a multi-center trial to test the efficacy of its Deep TMS device for the treatment of bipolar disorder, according to a filing today with the Tel Aviv Stock Exchange.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Alisa Odenheimer at aodenheimer@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.